valganciclovir

(redirected from Valcyte)
Also found in: Dictionary.

valganciclovir

 [val″gan-si´klo-vir]
a prodrug of ganciclovir, used in treatment of cytomegalovirus infections in immunocompromised patients; administered orally as the hydrochloride salt.

valganciclovir

/val·gan·ci·clo·vir/ (val″gan-si´klo-vir) a prodrug of ganciclovir, used as the hydrochloride salt in the treatment of cytomegalovirus retinitis in patients with AIDS.

valganciclovir

[val′gan-si′klo-vir]
a prodrug of ganciclovir, used in treatment of cytomegalovirus infections in immunocompromised patients and administered orally as the hydrochloride salt.

valganciclovir

A pro-drug of GANCICLOVIR used to treat CYTOMEGALOVIRUS INFECTION especially with retinitis. A brand name is Valcyte.
References in periodicals archive ?
For the most recent 12 months ending October 2014, the VALCYTE (Valganciclovir) tablets brand had US sales of about USD440m MAT, according to IMS Health.
Valcyte is a registered trademark of Genentech, Inc.
Valcyte is an antiviral medication that can be effective for the prevention of cytomegalovirus (CMV) disease in children from 4 months to 16 years of age who have undergone a kidney or heart transplant and who are at a higher risk of getting the disease.
The supplemental approval is based on data that showed longer prophylactic treatment with Valcyte reduced the incidence of CMV disease in high risk adult kidney transplant patients from 36.
His physician prescribed Valcyte for CMV, Kaletra for his HIV, and Neupogen to boost his white blood cell count.
Examples of these drugs include Zovirax (acyclovir) or its generic version acyclovir, Valtrex (valacyclovir), Cytovene (ganciclovir), Valcyte (valgancyclovir), and Vistide (cidofovir).
The drug is the generic version of Valcyte (Hoffmann La Roche) and is used to treat cytomegalovirus infection of the eye in patients with acquired immunodeficiency syndrome.
ANDA that had received approval, is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Valcyte of Hoffman-La Roche Inc.
M2 PHARMA-November 11, 2014-Endo wins final US FDA's approval for generic Valcyte
M2 EQUITYBITES-November 11, 2014-Endo wins final US FDA's approval for generic Valcyte
Pender, following his EBV-infected B cell model of autoimmunity, has had marginal success using the herpes class drugs Valcyte, Valtrex, Acyclovir, and so on.